Für Poster-/Präsentationen auf nationalen und internationalen Fachkongressen beachten Sie bitte unsere Beispiele auf der Seite Projekte.

Fachzeitschriften (Auswahl):

Monin M, Kümmerle T, Schneider J, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen B, Jessen H, Obst W, Spornraft-Ragaller P, Khaykin P, Balogh A, Wolf E, Bidner H, Spinner CD, Boesecke C; DUALIS STUDY GROUP. Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes. HIV Res Clin Pract. 2022 Mar 2:1-7. Epub ahead of print. PMID: 35234092.

Wolf E, Boesecke C, Balogh A, Bidner H, Cordes C, Heiken H, Krznaric I, Kümmerle T, Stellbrink HJ, Schneider J, Spinner CD; DUALIS Study Group. Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance. AIDS Res Ther. 2021 Sep 8;18(1):58. doi: 10.1186/s12981-021-00384-6. PMID: 34496848; PMCID: PMC8425038.

Valbert, Frederik; Wolf, Eva; Preis, Stefan; Schewe, Knud; Hanhoff, Nikola; Mück, Birgit; Lauscher, Paul; Rüsenberg, Robin; Wasem, Jürgen; Schellberg, Sven; Neumann, Anja. HIV-Epidemiologie in Deutschland: Späte Diagnostik. Dtsch Arztebl 2021; 118(43): A-1994 / B-1644

Hoffmann C, Wolf E. The Low Case Fatality Rate of Coronavirus Disease 2019 (COVID-19) in Hong Kong Could Be Deceptive. Clin Infect Dis. 2021 Oct 5;73(7):e1781-e1782. doi: 10.1093/cid/ciaa1676. PMID: 33119056; PMCID: PMC7665389.

Noe S, Schabaz F, Heldwein S, Mayer W, Ruecker K, Tiller FW, von Krosigk A, Wiese C, Balogh A, Gersbacher E, Jonsson-Oldenbuettel C, Jaeger H, Wolf E; ArcHIV study group.. HIV and SARS-CoV-2 co-infection: cross-sectional findings from a German ‚hotspot‘. Infection. 2021 Apr;49(2):313-320. doi: 10.1007/s15010-020-01564-8. Epub 2021 Jan 2. PMID: 33387261; PMCID: PMC7776282.

Funke B, Spinner CD, Esser S, Stellbrink HJ, Stoehr A, Wolf E, Koegl C, Bruening J, Witte V. High prevalence of recreational and illicit drug use in German people living with HIV with a potential for drug-drug interactions with antiretroviral therapy. Int J STD AIDS. 2021 Jan;32(1):75-82. doi: 10.1177/0956462420959169. Epub 2020 Nov 25. PMID: 33236659.

Hoffmann C, Wolf E. Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada. Infection. 2021 Feb;49(1):111-116. doi: 10.1007/s15010-020-01538-w. Epub 2020 Oct 24. PMID: 33098532; PMCID: PMC7585357.

Noe S, Ochana N, Wiese C, Schabaz F, Von Krosigk A, Heldwein S, Rasshofer R, Wolf E, Jonsson-Oldenbuettel C. Humoral response to SARS-CoV-2 vaccines in people living with HIV. Infection. 2021 Oct 25:1–7. doi: 10.1007/s15010-021-01721-7. Epub ahead of print. PMID: 34694595; PMCID: PMC8543429.

Valbert F, Wolf E, Preis S, Schellberg S, Schewe K, Hanhoff N, Mück B, Kögl C, Lauscher P, Wasem J, Neusser S, Neumann A. Understanding and avoiding late presentation for HIV diagnosis – study protocol of a trial using mixed methods (FindHIV). AIDS Care. 2021 Dec;33(12):1642-1646. doi: 10.1080/09540121.2021.1874276. Epub 2021 Jan 23. PMID: 33487003.

Olliges E, Bührlen B, Fischer F, Boesecke C, Kümmerle T, Schneider J, Weidlich S, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen BE, Wolf E, Ronel J, Spinner CD, On Behalf Of The Dualis Study Group. Health- related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study. AIDS Care. 2021 Apr 25:1-10. doi: 10.1080/09540121.2021.1916873. Epub ahead of print. PMID: 33896276.

Postel N, Wolf E, Balogh A, Obermeier M, Degen O, Mayr C, Baumgarten A, Pauli R, Mueck B, Jaeger H, Noe S. Functional Hypogonadism and Testosterone Deficiency in Aging Males With and Without HIV-infection. Exp Clin Endocrinol Diabetes. 2021 Nov;129(11):798-802. doi: 10.1055/a-1210-2482. Epub 2021 Jan 21. PMID: 33477181.


Spinner CD, Kümmerle T, Schneider J, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen B, Wyen C, Viehweger M, Lehmann C, Sprinzl M, Stoehr A, Bickel M, Jessen H, Obst W, Spornraft-Ragaller P, Khaykin P, Wolf E, Boesecke C; DUALIS Study Group. Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study. Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa356. doi: 10.1093/ofid/ofaa356. PMID: 32965277; PMCID: PMC7491710.

Wolf E, Noe S. Antivirale Therapie der Zukunft: Was ist in der Pipeline? : HIV-Therapie [Future prospects of antiviral HIV therapy: what is in the pipeline?]. MMW Fortschr Med. 2020 Jun;162(Suppl 2):50-54. German. doi: 10.1007/s15006-020-0647-9. PMID: 32583247.

Hoffmann C, Wolf E. SARS-CoV-2 seroprevalence in Spain. Lancet. 2020 Nov 7;396(10261):1484. doi: 10.1016/S0140-6736(20)32272-8. PMID: 33160562; PMCID: PMC7837169.Noe S, Jaeger H, Wolf E. Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis : Comment on „Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis“. Osteoporos Int. 2019 Aug;30(8):1705-1706.

Bickel M, Hoffmann C, Wolf E, Baumgarten A, Wyen C, Spinner CD, Jäger H, Postel N, Esser S, Mueller M, Stoehr A, Preis S, Klauke S, Schewe K; PROPHET study group of dagnae e.V.. High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort study. Infection. 2020 Jun;48(3):453-461. doi: 10.1007/s15010-020-01428-1. Epub 2020 May 11. PMID: 32394345.

Weidlich S, Boesecke C, Schneider J, Klinker HHF, Zink A, Balogh A, Wolf E, Bidner H, Spinner CD; DUALIS study team. Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study. J Antimicrob Chemother. 2020 Oct 1;75(10):3082-3084. doi: 10.1093/jac/dkaa234. PMID: 32634214; PMCID: PMC7678892.

Valbert F, Wolf E, Schewe K, Klauke S, Hanhoff N, Hoffmann C, Preis S, Pahmeier K, Wasem J, Neumann A. Cost of Human Immunodeficiency Virus (HIV) and Determinants of Healthcare Costs in HIV-Infected Treatment-Naive Patients Initiated on Antiretroviral Therapy in Germany: Experiences of the PROPHET Study. Value Health. 2020 Oct;23(10):1324-1331. doi: 10.1016/j.jval.2020.04.1836. Epub 2020 Aug 14. PMID: 33032776.


Christensen S, Wolf E, Altevers J, Diaz-Cuervo H. Comorbidities and costs in HIV patients: A retrospective claims database analysis in Germany. PLoS One. 2019 Nov 6;14(11):e0224279. doi: 10.1371/journal.pone.0224279. eCollection 2019.

Noe S, Jaeger H, Wolf E. Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis : Comment on „Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis“. Osteoporos Int. 2019 Aug;30(8):1705-1706.

Noe S, Heldwein S, Jaeger H, Page M, Wolf E. Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine – results from a German cohort study. Int J STD AIDS. 2019 Apr;30(5):447-452. doi: 10.1177/0956462418815022. Epub 2019 Jan 10.


Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C. Reply to Letter ‚Morning dosing for dolutegravir-related insomnia and sleep disorders‘ by Capetti et al. HIV Med. 2018 May;19(5):e60-e61. doi: 10.1111/hiv.12539. Epub 2017 Aug 29. PMID: 28851009.

Ronel J, Dinkel A, Wolf E, Marten-Mittag B, Mueck B, Mayr C, Hoffmann C, Karwat M, Schewe K, Baumgarten A, Jaeger H. Anxiety, depression, and health-related quality of life in aging people living with HIV compared to diabetes patients and patients with minor health conditions: a longitudinal study. Psychol Health Med. 2018 Aug;23(7):823-830.

Noe S, Heldwein S, Wiese C, Pascucci R, von Krosigk A, Schabaz F, Jonsson-Oldenbuettel C, Jaeger H, Wolf E. Tenofovir Disoproxil Fumarate Is Associated with a Set-Point Variation in the Calcium-Parathyroid Hormone-Vitamin D Axis: Results from a German Cohort. Adv Pharmacol Sci. 2018 Dec 31;2018:6069131. doi: 10.1155/2018/6069131. eCollection 2018.

Noe S, Moeckel CI, Schwerdtfeger C, Oldenbuettel C, Jaeger H, Wolf E, Spinner CD. Monthly or Weekly Supplementation with Cholecalciferol 20,000 IU in People Living with HIV: Results from a Nested Cohort Study. Interdiscip Perspect Infect Dis 2018 Sep 2;2018:7502127. doi: 10.1155/2018/7502127. eCollection 2018.

Spinner CD, Schulz S, Bauer U, Schneider J, Bobardt J, Von Werder A, Schmid RM, Zink A, Wolf E, Iakoubov R. Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: the TAF-IR Study. Antivir Ther. 2018;23(7):629-632. doi: 10.3851/IMP3271. Epub 2018 Oct 3.

Noe S, Oldenbuettel C, Heldwein S, Wiese C, von Krosigk A, Pascucci R, Ruecker K, Jaeger H, Wolf E. Secondary Hyperparathyroidism in HIV-Infected Patients in Central Europe. Horm Metab Res. 2018 Jan 23. doi: 10.1055/s-0043-125073. [Epub ahead of print] PubMed PMID: 29361637.

2017 und älter

  • Spinner CD, Kümmerle T, Krznaric I, Degen O, Schwerdtfeger C, Zink A, Wolf E, Klinker HHF, Boesecke C. Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study. J Antimicrob Chemother. 2017 Sep 1;72(9):2679-2681.
  • Boretzki J, Wolf E, Wiese C, Noe S, Balogh A, Meurer A, Krznaric I, Zink A, Lersch C, Spinner CD. Highly specific reasons for nonadherence to antiretroviral therapy: results from the German adherence study. Patient Prefer Adherence. 2017, 11:1897-1906.
  • Noe S, Oldenbuettel C, Heldwein S, Jaeger H, Wolf E. Patterns of vitamin D, parathyroid hormone and c-terminal telopeptide of collagen type 1 in Caucasian and African descent HIV-infected populations in Central Europe. Infect Dis Rep. 2017 Oct 2;9(3):7265.
  • Wolf E, Noe S. [Long-acting shot against HIV]. MMW Fortschr Med. 2017, 159(Suppl 2):36-38.
  • Wolf E, Noe S. Therapie und Prävention: Depotspritze gegen HIV. MMW Fortschritte der Medizin 2017. S2 / 159: 36-37 (in press) .
  • Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink HJ, Wyen C. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017 Jan;18(1):56-63. doi:10.1111/hiv.12468. PubMed PMID: 27860104.
  • Noe S, Heldwein S, Pascucchi R, Oldenbüttel C, Wiese C, von Krosigk A, Jägel-Guedes E, Jäger H, Mayer W, Spinner CD, Wolf E. Cholecalciferol 20 000 IU Once Weekly in HIV-Positive Patients with Low Vitamin D Levels: Result from a Cohort Study. J Int Assoc Provid AIDS Care. 2017 Jan 1:2325957417702487.
  • Oldenbuettel C, Wolf E, Ritter A, Noe S, Heldwein S, Pascucci R, Wiese C, Von Krosigk A, Jaegel-Guedes E, Jaeger H, Balogh A, Koegl C, Spinner CD. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Antivir Ther. 2017;22(2):169-172. doi: 10.3851/IMP3082. Epub 2016 Sep 2.
  • Spinner CD, Kern KE, Zink A, Wolf E, Balogh A, Noe S, Von Werder A, Schwerdtfeger C, Schmid RM, Iakoubov R. Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study. Antivir Ther. 2016;21(7):627-631. doi: 10.3851/IMP3049. PubMed PMID: 27050630.
  • Hoffmann C, Schommers P, Wolf E, Müller M, Schultze A, Krznaric I, Stoehr A, Wolf T, Fäktenheuer G, Stier B, Wyen C, Hentrich M. CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. AIDS. 2016 Mar 13;30(5):753-60. doi: 10.1097/QAD.0000000000000980.
  • Wolf E, Hoffmann C, Schewe K, Klauke S, Baumann R, Karwat M, Schlote F, Mosthaf F, Heiken H, Baumgarten A, Ulmer A, and Jaeger H for the dagnae 50/2010 study group. Symptom and Comorbidity Burden in Chronic Disease: Comparison of HIV-Infection and Diabetes Mellitus in Aging Patients. J AIDS Clin Res 2015; 6: 527. doi:10.4172/2155-6113.1000527.
  • Enders M, Hunjet A, Gleich M, Imdahl R, Mühlbacher A, Schennach H, Chaiwong K, Sakuldamrongpanich T, Turhan A, Sertöz R, Wolf E, Mayer W, Tao C, Wang LL, Semprini S, Sambri V. Performance evaluation of the Elecsys® syphilis assay for the detection of total antibodies to Treponema pallidum. Clin Vaccine Immunol. 2015 Jan;22(1):17-26. doi: 10.1128/CVI.00505-14.
  • Wolf E, Jaeger H. The Concept of the New ERA Study. MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:24-6. German.
  • Hoffmann C, Kohrs F, Sabranski M, Wolf E, Jaeger H, Wyen C, Siehl J, Baumgarten A, Hensel M, Jessen A, Schaaf B, Vogel M, Bogner J, Horst HA, Stephan C. HIV-associated lung cancer: survival in an unselected cohort. Scand J Infect Dis. 2013 Oct;45(10):766-72.
  • Dinkel A, Nather C, Jaeger H, Jaegel-Guedes E, Lahmann C, Steinke C, Wolf E, Ronel J. Stigmatization in HIV/AIDS: first German adaptation of the HIV-stigma scale (HSS-D). Psychother Psychosom Med Psychol. 2014 Jan;64(1):20-7. doi: 10.1055/s-0033-1341449. Epub 2013 May 15. German.
  • Mostardt S, Hanhoff N, Wasem J, Goetzenich A, Schewe K, Wolf E, Mayr C, Jaeger H, Pfaff H, Dupke S, Neumann A. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study. Eur J Health Econ. 2013 Oct;14(5):799-808. doi: 10.1007/s10198-012-0425-4. Epub 2012 Sep 19.
  • Obermeier M, Pironti A, Berg T, Braun P, Däumer M, Eberle J, Ehret R, Kaiser R, Kleinkauf N, Korn K, Kücherer C, Müller H, Noah C, Stürmer M, Thielen A, Wolf E, Walter H. HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge. Intervirology. 2012;55(2):102-7.
  • Mostardt S, Hanhoff N, Wasem J, Goetzenich A, Schewe K, Wolf E, et al. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNA K3A Study. Eur J Health Econ 2012.
  • Obermeier M, Ehret R, Berg T, Braun P, Korn K, Muller H, Noah C, Stürmer M, Thielen A, Walter H, Wolf E, Kaiser R. Genotypic HIV-coreceptor tropism prediction with geno2pheno [coreceptor]: differences depending on HIV-1-subtype. J Int AIDS Soc 2012; 15(6):18214.Knechten H, Stephan C, Mosthaf FA, Jaeger H, Carganico A, Lutz T, Schewe K, Mayr C, Wolf E, Wellmann E, Tappe A. The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients. Eur J Med Res. 2011 Mar 28;16(3):93-100.
  • Glaubitz J, Sizmann D, Simon CO, Hoffmann KS, Drogan D, Hesse M, et al. Accuracy to 2nd International HIV-1 RNA WHO Standard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification tests. J Clin Virol 2011; 50(2):119-124.
  • Plettenberg A, Brockmeyer NH, Haastert B, Michalik C, Dupke S, Schewe K, Rausch M, Hower M, Ulmer A, Wolf E, Lorenzen T, Arendt G, Jansen K; Competence Network for HIV/AIDS. Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS. Infection 2011; 39(1):3-12.
  • Mueller SM, Spriewald BM, Bergmann S, Eismann K, Leykauf M, Korn K, et al. Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognition. J Acquir Immune Defic Syndr 2011; 56(2):109-117.
  • Jaeger H, Wolf E, Simon CO, Babiel R. Traceability of 3 generations of nucleic acid amplification tests for quantitative HIV-1 RNA measurements to meet the WHO HIV-1 RNA International Standards. J Acquir Immune Defic Syndr 2010; 54(3):334-335.
  • Wolf E, Blankenburg M, Bogner JR, Becker W, Gorriahn D, Mueller MC, et al. Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res 2010; 15(4):145-151.
  • Knechten H, Stephan C, Mosthaf FA, Jaeger H, Lutz T, Cargnico A, et al. Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naive or pretreated but protease inhibitor-naive HIV-positive patients. Infection 2010; 38(2):108-116.
  • Opravil M, Klimkait T, Louvel S, Wolf E, Battegay M, Fux CA, et al. Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2010; 54(1):51-58.
  • Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K, Rausch M, et al. Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort. Eur J Med Res 2009; 14(7):277-283.
  • Kastenbauer U, Wolf E, Kollan C, Hamouda O, Bogner JR. Impaired CD4-cell immune reconstitution upon HIV therapy in patients with toxoplasmic encephalitis compared to patients with pneumocystis pneumonia as AIDS indicating disease. Eur J Med Res 2009; 14(6):244-249.
  • Mauss S, Berger F, Kuschak D, Henke J, Hegener P, Wolf E, et al. Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients. Antivir Ther 2008; 13(8):1091-1095.
  • Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007; 8(5):679-688.
  • Hoffmann C, Ernst M, Meyer P, Wolf E, Rosenkranz T, Plettenberg A, et al. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses. Clin Microbiol Infect 2007; 13(5):510-515.
  • Hoffmann C, Stellbrink HJ, Dielschneider T, Degen O, Stoehr A, Knechten H, et al. Adoptive transfer of syngeneic T cells in HIV-1 discordant twins indicates rapid regulation of T-cell homeostasis. Br J Haematol 2007; 136(4):641-648.
  • Hoffmann C, Wolf E, Wyen C, Fatkenheuer G, van LJ, Stellbrink HJ, et al. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma 2006; 47(9):1872-1880.
  • Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von BF, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20(15):1951-1954.
  • Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H. [High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review]. Dtsch Med Wochenschr 2006; 131(34-35):1849-1852.
  • Fehr JS, Nicca D, Sendi P, Wolf E, Wagels T, Kiss A, et al. Starting or changing therapy – a prospective study exploring antiretroviral decision-making. Infection 2005; 33(4):249-256.
  • Wolf E, Hoffmann C, Procaccianti M, Mosthaf F, Gersbacher E, Ulmer A, et al. Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. Eur J Med Res 2005; 10(2):56-62.
  • Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van LJ, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin’s disease. Br J Haematol 2004; 125(4):455-462.
  • Mauss S, Scholten S, Wolf E, Berger F, Schmutz G, Jaeger H, et al. A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir. HIV Med 2004; 5(1):15-17.
  • Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17(10):1521-1529.
  • Mauss S, Wolf E, Hans J. Changing incidence of mycobacterial diseases in German patients with HIV infection. AIDS Read 1999; 9(6):386, 391-386, 392.
  • Mauss S, Corzillius M, Wolf E, Schwenk A, Adam A, Jaeger H, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Med 2002; 3(1):49-55.
  • Hoffmann C, Tabrizian S, Wolf E, Eggers C, Stoehr A, Plettenberg A, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 2001; 15(16):2119-2127.